$OPRX News

OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

OptimizeRx (OPRX) Stock Sees Fair Value Cut As Analysts Reset Growth Expectations

OptimizeRx: A Good Business That Has Not Yet Earned Back Investor Trust

OptimizeRx to Participate in Upcoming Investor Conferences

DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network

OptimizeRx's Electronic Health Record Network Integrated By DeepIntent

Some OptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Made A Major Cut To Next Year's Estimates

OptimizeRx (OPRX) Q1 2026 Earnings Transcript

Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11

B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10

Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14

OptimizeRx Corp (OPRX) Q1 2026 Earnings Call Highlights: Strong AI Growth Amid Revenue Challenges

OptimizeRx Q1 Earnings Call Highlights

OptimizeRx Corporation Q1 2026 Earnings Call Summary

OptimizeRx Corp (NASDAQ:OPRX) Beats Q1 Estimates But Slashes 2026 Revenue Guidance